Palatin Technologies, Inc. rose 15.3% on Wednesday, November 4, 2026, on 48,300 shares. No headline about PTN came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Palatin Technologies, Inc. (PTN:NYSEMKT) closed at $6.89 on November 10, 2026, down 4.70% on the day. The stock trades 77.8% below its 52-week high of $31.00 and 52.8% above its 52-week low of $4.51. Over the past year, it lost 28.1%. Palatin Technologies, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, PTN closed higher on 109 days (43%). Its best day was November 21, 2025 (+57.49%) and its worst was September 15, 2026 (-18.11%). The stock moved 10% or more in a single session 33 times. It opened at least 5% above the previous day's high 2 times.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. In addition, the company is involved in the development of natriuretic peptide receptor-specific programs, including PL-3994, a natriuretic peptide receptor-A, which is in Phase II clinical studies for treatment of heart failure, acute exacerbations of asthma, and refracto...
Find more stocks like PTN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.